Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib

Despite the benefit with cancer immunotherapies in clinical implication, immunotherapeutic resistance occurred in many patients and the mechanism remains unknown. Increasing evidence has revealed that cell‐intrinsic programmed cell death ligand 1 (PD‐L1) may play a non‐negotiable part in immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yuan, Feng, Yingfang, Liu, Shaochuan, Zhang, Yan, Wang, Jing, Qin, Tingting, Chen, Peng, Li, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417303/
https://www.ncbi.nlm.nih.gov/pubmed/37350549
http://dx.doi.org/10.1002/cam4.6195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417303/
https://www.ncbi.nlm.nih.gov/pubmed/37350549
http://dx.doi.org/10.1002/cam4.6195

Ejemplares similares